Avricore Health Inc. AVCR

VANCOUVER, British Columbia, Sept. 01, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) is pleased to announce that NHS England has confirmed the national expansion of the Barts Health pharmacy cholesterol testing programme powered by Avricore’s HealthTab™ platform. Approximately 100 pharmacies across England will begin offering seven-minute cholesterol checks this fall as part of a national NHS initiative aimed at identifying cardiovascular risk earlier and reducing heart attacks and

VANCOUVER, British Columbia, Aug. 28, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) today announces that the Company’s board of directors has approved the granting of stock options (the “Options”) exercisable for a total of 3,300,000 common shares to its directors, officers, employees and consultants at an exercise price of CAD $0.06 per common share. All Options were granted pursuant to the Company’s stock option plan and are subject to the terms of the applicable grant agreements

Healthcare stocks declined Thursday afternoon, with the NYSE Healthcare Index decreasing 0.7% and th

VANCOUVER, British Columbia, Aug. 20, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) is pleased to announce that its wholly-owned subsidiary, HealthTab Ltd, has entered into a formal collaboration agreement with Abbott, a global healthcare company, to supply and distribute Abbott’s point-of-care testing products through the HealthTab™ platform in the UK. The agreement allows HealthTab to distribute Abbott’s Afinion™ 2 Analyzer in NHS-linked pharmacies to test for HbA1c and lipid prof

VANCOUVER, British Columbia, June 17, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “Avricore”) announces that, further to its news release dated May 20, 2026, the Company has closed its non-brokered private placement for gross proceeds of $1,254,000 by issuing 25,080,000 Units at $0.05 per Unit on June 16, 2026. Rodger Seccombe, CEO of Avricore stated, "This financing provides the Company with the capital strength for its UK expansion. We appreciate the commitment

VANCOUVER, British Columbia, May 20, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “Avricore”) announces a non-brokered private placement of up to 25,000,000 units ("Units") at a price of $0.05 per unit for gross proceeds of $1,250,000. (the "Private Placement"). The proceeds will be used to expand the Company’s HealthTab™ network and for general working capital purposes. Each Unit consists of one common share and one half transferrable share purchase warrant. Each

Avricore Health (AVCR.V) said Tuesday that its HealthTab platform has now screened more than 3,500 p

VANCOUVER, British Columbia, April 21, 2026 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “Avricore”) announces HealthTab™ has now screened more than 3,500 patients in community pharmacies across North East and North Central London. During an initial one-month pilot of HbA1c testing for diabetes screening, the Company completed 2,295 HbA1c tests across 57 locations, achieving a monthly per-location average 10 times higher than previously achieved in Canada. Expansion Ro

Bringing Cholesterol-Lowering Injections to U.K. Community PharmaciesVANCOUVER, British Columbia, Nov. 27, 2025 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “Avricore”) is pleased to announce HealthTab™ is being deployed in a new pilot launched by Barts Health NHS Trust, in collaboration with UCL Partners and the British Heart Foundation (BHF), to deliver inclisiran cholesterol-lowering injections through community pharmacies. Key Highlights HealthTab™ enters secondary